The presence of insulin resistance (IR) appears to be a key factor in the development of
steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1
infections similar to levels in Non-alcoholic fatty liver disease (NAFLD). The objective of
this study is to determine whether Pioglatizone, when given along with Interferon and
Ribavirin, reduces insulin resistance and lowers HCV viral levels and improved response in
patients who have HCV genotype-1 infection when compared to a placebo.